医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories Limited to Present at the Jefferies 2017 Global Healthcare Conference

2017年06月06日 AM01:55
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th, 2017, in New York City.

The presentation is scheduled to begin at 4:30 p.m. EDT [2:00 a.m. IST on June 7th, 2017].

Presentation material will be available on the Company’s website www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170605005925/en/

CONTACT

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK
SAVLA, +91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER, +91-40-49002121
calvinprinter@drreddys.com

同じカテゴリーの記事 

  • Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
  • Avistone Announces Results from a Sponsored Clinical Research Program Studying the Combination of Two Small-Molecule c-MET and EGFR Inhibitors in NSCLC Patients at the 2024 World Conference on Lung Cancer (WCLC)
  • CorFlow Therapeutics AG完成4400万欧元B轮融资,以支持发展针对心脏病发作患者微血管阻塞(MVO)的新型诊断和药物递送平台
  • 诺为泰凭借其生物技术CRO服务方面的领导力荣膺Frost & Sullivan“2024全球年度公司奖”
  • CorFlow Therapeutics AG、心臓発作患者における微小血管閉塞(MVO)の新規診断・薬物送達プラットフォームの開発を支援するため4400万ユーロのシリーズB資金調達を完了